

Daily evidence digest

24 May 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Vaccine hesitancy practice pointer, excess deaths in 29 high-income countries, post-acute COVID-19

Peer reviewed journals featured:

- A BMJ practice pointer on COVID-19 vaccination hesitancy [here](#)
- A narrative review on telemedicine and primary care in South East Asia [here](#)
- Observational studies on:
 - Excess deaths in 29 high-income countries associated with COVID-19 [here](#) and [here](#)
 - Post-acute COVID-19 syndrome in non-hospitalised patients [here](#)
 - Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection [here](#) and [here](#)
 - Impact of vitamin D therapy on the inflammatory markers in COVID-19 patients [here](#)
 - The SARS-CoV-2 variant P1 (Brazil) in South America [here](#)
- Modelling studies on
 - Face mask effectiveness in mitigating SARS-CoV-2 transmission [here](#)
 - Controlling COVID-19 via test-trace-quarantine [here](#)
- Editorials on:
 - The change of stance on mask use from the US Centers for Disease Control [here](#)
 - Prioritising prevention [here](#)
- Commentaries on:
 - Post-exposure vaccination [here](#)

Letters and correspondence discussed:

- Preliminary analysis on sudden hearing loss associated with COVID-19 vaccination [here](#)

Pre-peer review articles featured:

- Surface and air contamination with SARS-CoV-2 from hospitalised patients in Toronto [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce updated recommendations and clinical flowcharts [here](#)

News and blogs

- Moral injury inflicted on senior hospital doctors in the UK [here](#)
- Call for military-style mental health support for critical care staff in the UK [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.